Market Report Source

Overview

Introduction

Neurogen is a drug discovery and development company founded in 1987. The company established its presence in the pharmaceutical market by partnering with Pfizer and American Home Products in 1999. In addition, the company’s proprietary technology, Accelerated Intelligent Drug Discovery (AIDD), is the result of a successful collaboration with Merck for VR-1 research programs.

Scope

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies

Highlights

Neurogen is focused on developing small molecule drugs for disorders with unmet medical need, including insomnia, pain, obesity, depression and inflammation. The company utilizes its proprietary technology, Accelerated Intelligent Drug Discovery (AIDD), for discovering and optimizing potential drug leads. The key elements of the company’s business strategy include: advancing clinical development of its product candidates, acquiring potential product candidates through licensing agreements and continue to maximize the success of VR-1 research program with Merck. The company’s total revenues declined at a CAGR of 11.1% during 2002-2006, from $15.7 million to $9.8 million. This represents an absolute total decline of -$5.9 million for total revenues. The decline is primarily due to the termination of the company’s research collaboration with Aventis in September 2004.

Reasons to Purchase

Access all the important information and analysis on the company in a single report Understand company’s strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company’s adjusted five year financial data along with key ratios and market capitalization.

Table of Contents

Overview
Catalyst
Summary
Company Structure
Company Overview and Key Facts
Business Description
History
Locations and Subsidiaries
Company Financials
Stock Market Performance
P&L
Balance Sheet
Cash Flow
Business Segment Performance
Products & Services
Pipeline Products
AC Forecast Product Sales
Competitors and Strategic Business Relationships
Key Competitors
Key Suppliers
Key Clients
Shareholding Structure
Strategy
Company View
Corporate Strategy
SWOT Analysis
Overview
Strengths
Weaknesses
Opportunities
Threats
Value Chain Analysis
Overview
Discovery and Product Development
Scorecard
Overview
Scorecard Analysis
Key Employees
List of Key Employees
Key Employee Biographies
Financial and Operational Overview
Financial and Operational Overview

APPENDIX
Ask the analyst
Datamonitor consulting
Disclaimer

FIGURES
Figure 1: Neurogen – Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)

TABLES
Table 1: Neurogen – Key Facts
Table 2: Neurogen – Locations and Subsidiaries
Table 3: Neurogen – Year-End Share Price and Market Capitalization, 2002-2006 ($)
Table 4: Neurogen – Key Events Impacting Share Price Performance
Table 5: Neurogen – Operating Cost Ratio Analysis, 2002-2006 (% of total revenues)
Table 6: Neurogen – Operating Cost Ratio Analysis, 2002-2006 (% of total revenues)
Table 7: Neurogen – Balance Sheet, 2002-2006 ($ Mn)
Table 8: Neurogen – Cash Flow, 2002-2006 ($ Mn)
Table 9: Neurogen – Revenue Breakdown by Division, 2002-2006 ($ Mn)
Table 10: Neurogen – In-house Pipeline Products
Table 11: Neurogen – Collaboration Products
Table 12: Neurogen – Forecast Sales, 2006-2010 ($ Mn)
Table 13: Neurogen – Key Competitors
Table 14: Neurogen – Key Suppliers
Table 15: Neurogen – Key Clients
Table 16: Neurogen – Key Shareholders
Table 17: Neurogen – SWOT Analysis Summary
Table 18: Neurogen – Value Chain Analysis
Table 19: Neurogen – Scorecard
Table 20: Neurogen – Key Employees
Table 21: Neurogen – Financial and Operational Overview